Pharma & Biotech - Page 34

GSK is preparing to seek FDA accelerated approval for its cancer drug Jemperli after a phase 2 trial delivered a significant clinical win in a high-profile cancer indication. Interim results from the

Insulet Corporation (NASDAQ: PODD), maker of the Omnipod tubeless insulin pump, has announced a global partnership with mental health app Calm to support the emotional wellbeing of people living with diabetes. The

Lupin Pharmaceuticals, the U.S. unit of India-based Lupin Limited, has issued a voluntary recall of more than 2.5 million bottles of prescription eye drops following the discovery of an undisclosed contaminant. The

Pharmaceutical manufacturers are increasingly turning to reusable plastic pallets as pressure mounts to deliver high-value products safely, sustainably, and efficiently. ORBIS Corporation strategic account manager Matt Marchetti says the shift reflects growing

The U.S. Food and Drug Administration has issued a proposed rule that would create a streamlined registration pathway for distributed drug manufacturing establishments operating under a hub-and-spoke model. Under the current regulatory

Hengrui Pharma and Elevar Therapeutics have received a third complete response letter from the FDA for their camrelizumab and rivoceranib combination therapy. The rejection marks more than two years of regulatory setbacks

Lawmakers have introduced the first comprehensive bipartisan legislation to overhaul the 340B Drug Pricing Program since its creation more than three decades ago. US Representatives Jake Auchincloss, Scott Peters, and Dr. John

BioMarin has launched a three-episode video podcast series called “Why Do I Pheel This Way?” aimed at teens living with phenylketonuria, known as PKU. The campaign centres on real conversations about the

As access to GLP-1 medications widens across the United States, pharmacies are emerging as one of the most important pillars of long-term treatment success. Medicare’s expansion of GLP-1 access, including pathways toward

Bayer has agreed a €3 billion ($3.4 billion) equity deal with New York-based asset manager Apollo for a minority stake in its long-acting reversible contraceptives business. The German pharmaceutical giant will retain